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Stromal expression of hypoxia inducible factor 2a (HIF-2a) and carbonic anhydrase 9 (CA9) are associated with a poorer prognosis
in colorectal cancer (CRC). Tumour cell death, regulated by a hypoxic stromal microenvironment, could be of importance in this
respect. Therefore, we correlated apoptosis, TP53 mutational status and BNIP3 promoter hypermethylation of CRC cells with
HIF-2a- and CA9-related poor outcome. In a series of 195 CRCs, TP53 mutations in exons 5–8 were analysed by direct sequencing,
and promoter hypermethylation of BNIP3 was determined by methylation-specific PCR. Expressions of HIF-2a, CA9, p53, BNIP3 and
M30 were analysed immunohistochemically. Poorer survival of HIF-2a and CA9 stromal-positive CRCs was associated with wild-type
TP53 (P¼0.001 and P¼0.0391), but not with BNIP3 methylation. Furthermore, apoptotic levels were independent of the TP53
status, but lower in unmethylated BNIP3 CRCs (P¼0.004). It appears that wild-type TP53 in CRC cells favours the progression of
tumours expressing markers for hypoxia in their stroma, rather than in the epithelial compartment. Preserved BNIP3 function in CRC
cells lowers apoptosis, and may thus be involved in alternative cell death pathways, such as autophagic cell death. However, BNIP3
silencing in tumour cells does not impact on hypoxia-driven poorer prognosis.
These results suggest that the biology of CRC cells can be modified by alterations in the tumour microenvironment under conditions
of tumour hypoxia.
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Hypoxia has been reported to influence tumour biology in
opposing ways. It can directly induce cell death by activating
apoptosis or autophagy, yet hypoxic zones in solid tumours also
harbour viable cells resistant to treatment, which contributes to
poor patient outcome (Erler et al, 2006). Hypoxia influences the
expression of genes involved in cell death and energy homeostasis
mainly by stabilisation and activation of the hypoxia inducible
factor (HIF) family of transcription factors, influencing angio-
genesis (VEGF), glycolysis (GLUT1), pH regulation (CA9),
apoptosis (TP53, BNIP3) and autophagy (BNIP3) (Bacon and
Harris, 2004; Keith and Simon, 2007).
A common hallmark of solid tumours under hypoxic stress is
increased ATP requirement, which is supplied by the induction of
anaerobic glycolysis. This subsequently leads to a high production
of intracellular lactate, requiring regulation of intracellular pH,
a process mediated partly by HIF-dependent upregulation of
carbonic anhydrase 9 (CA9). Carbonic anhydrase 9 catalyzes
the extracellular trapping of acid by hydrating cell-generated
CO2 into HCO3
  and H
þ (Swietach et al, 2007). Consequently,
CA9 expression may serve as a marker for metabolic adaptation
during hypoxia.
Upregulation of p53 and BNIP3 proteins, which stimulate cell
death via apoptosis and/or autophagy, appears contradictory to the
adverse association between tumour hypoxia and prognosis.
However, it was suggested that through induction of cell death,
hypoxia selects for cells with defective cell death regulators, such
as TP53 (Graeber et al, 1996). In non-selected cells hypoxia can
induce expression of p53 and activate p53-mediated G0/G1 arrest
or apoptosis, although secondary effects, such as extracellular
acidosis and glucose deprivation, are necessary for p53-mediated
apoptosis (Graeber et al, 1996; Schmaltz et al, 1998; Pan et al, 2004;
Toledo and Wahl, 2006). Over 50% of human tumours contain
somatic mutations in the TP53 gene, resulting in a defective
apoptotic response (Kato et al, 2003; Soussi and Lozano, 2005).
Therefore, TP53 mutations are expected to decrease the suscept-
ibility of tumour cells to hypoxia-induced cell death, as shown
in vitro (Graeber et al, 1996; Fei et al, 2004). BNIP3 is a Bcl-2 family
member, containing a single BcL-2 homology 3 (BH3) domain and
a transmembrane domain localising it to the outer mitochondrial
membrane (Vande Velde et al, 2000; Lee and Paik, 2006). It is
activated by HIF during hypoxia and initiates programmed cell
death through apoptosis or autophagy (Ray et al, 2000; Mellor and
Harris, 2007). Epigenetic silencing of BNIP3 by promoter
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shypermethylation has been reported in several cancer types and
contributes to resistance to hypoxia-induced cell death (Okami
et al, 2004; Abe et al, 2005; Yan et al, 2006). The role of BNIP3 in
colorectal cancer (CRC) is unknown, although 66% tumours show
BNIP3 silencing by promoter hypermethylation (Murai et al, 2005;
Bacon et al, 2007).
Usually, the effects of hypoxia in solid tumours are studied
within the tumour cells themselves, neglecting the hypoxic
response in tumour-associated stroma. In a previous study, we
found that hypoxia within the tumour-associated stroma is indeed
correlated with a poorer outcome in patients with CRC who are
treated by surgery alone. In a multivariate model, stromal
expressions of both HIF-2a and CA9 were independent adverse
prognostic factors, whereas HIF-1a was not. Furthermore, expres-
sion of hypoxia-related proteins HIF-1a, GLUT1 and CA9 in the
tumour cells self was not associated with poorer patient survival
(Cleven et al, 2007).
Our previous findings indicate that hypoxic conditions may
modulate the tumour stroma in such a way that a more aggressive
tumour behaviour is facilitated, ultimately leading to decreased
patient survival.
This study attempts to elucidate whether changes in the
epithelial cell compartment of CRC, such as apoptosis and
concomitant (epi)genetic changes that are confined to the tumour
cells, are related to hypoxia-related changes in the stromal
compartment. For this purpose, we correlated alterations of TP53
and BNIP3 in tumour cells with expression of hypoxia-related
proteins HIF-2a and CA9 in relation with patient outcome and
apoptotic activity in CRCs.
PATIENTS AND METHODS
Patient population
Patients were registered for two multicentre prospective clinical
trials in The Netherlands between 1979 and 1981. One trial was
designed to compare patient survival after treatment of colon
cancer by conventional surgery or the no-touch isolation
technique (Wiggers et al, 1988). The second trial was conducted
to compare survival in rectal cancer patients with or without
preoperative radiotherapy. In the current study, we included only
the patients who did not undergo preoperative radiotherapy. At
the time the trial was conducted, only surgical removal of the
tumours was performed, and adjuvant chemotherapy was not yet a
standard practice. This study population therefore enables
unbiased study of the influence of hypoxic conditions on tumour
biology.
Tumour tissues were fixed in buffered formalin, sectioned
and embedded in paraffin. Experienced pathologists documented
the histopathological characteristics of the tumours (Table 1).
Follow-up took place every 3 months during the first 3 years
and every 6 months between 3 and 5 years after initial diagnosis
and surgery. Standard protocols were followed, with routine
blood counts and chemical studies (including CEA levels) at
each visit, and liver ultrasound, chest X-ray and colonoscopy
annually, to evaluate recurrence of disease and disease-related
death. After a 5-year follow-up period, only time and cause of
death were registered. Follow-up was complete for all patients.
Failure was defined as death due to recurrent disease, excluding
postoperative mortality within 30 days and non-disease-related
death.
For immunohistochemical and molecular analyses, tumour
tissues from 195 CRC patients were available. The distribution
of age, gender, tumour stage, location and type of tumour,
frequency of events and mean follow-up time of the patients in
this study are representative of the patients in the trial (see
Table 1).
Genomic DNA isolation
Genomic DNA was extracted from CRC tissues using PureGenet
genomic DNA isolation kit (Gentra Systems, Minneapolis, MN,
USA) based on the manufacturer’s protocol.
TP53 sequencing
Mutation analyses of TP53 exons 5–8 were performed using a
semi-nested PCR approach, (see Supplementary Table 1 for primer
sequences). Caco2 (exon 6, codon 204 nonsense mutation) was
included as a control. Direct sequencing of PCR products was
performed using the BigDye
s terminator v1.1 cycle sequencing kit
(Applied Biosystems, Foster City, CA, USA) and analysed on the
ABI 3730 DNA Analyzer (Applied Biosystems). Mutation was
detected using Mutation Surveyor DNA Variant Analysis Software
v3.0 (SoftGenetics LLC, State College, PA, USA). The results of the
mutation analyses are listed in Table 2. Furthermore, we assessed
whether TP53 missense mutants were transcriptionally active, on
the basis of the IARC prediction models (http://p53.iarc.fr/
MutationValidationCriteria.asp). Missense mutations were classi-
fied as either transactivation-incompetent or transactivation-
competent missense mutations.
BNIP3 promoter methylation analysis
BNIP3 promoter methylation was determined by sodium bisul-
phite modification of genomic DNA using the EZ DNA methyla-
tion kit (ZYMO Research Co., Orange, CA). Methylation-specific
Table 1 TP53 mutation analyses, BNIP3 methylation and clinicopatho-
logical characteristics
TP53 BNIP3
Wt Mutant U M
No. % No. % P No. % No. % P
Total patients 78 (50) 77 (50) 92 (47) 103 (53)
Age (years) 0.297 0.759
o69 35 (45) 41 (53) 44 (48) 47 (46)
469 43 (55) 36 (47) 48 (52) 56 (54)
Sex 0.942 0.788
Male 35 (45) 35 (45) 42 (46) 49 (48)
Female 43 (55) 42 (55) 50 (54) 54 (52)
Tumour location 0.202 0.016
Proximal 32 (41) 24 (31) 25 (27) 45 (44)
Distal 46 (59) 53 (69) 67 (73) 58 (56)
Tumour 0.819 0.967
Colon 49 (63) 47 (61) 61 (66) 68 (66)
Rectum 29 (37) 30 (39) 31 (34) 35 (34)
Differentiation 0.913 0.959
Well 8 (10) 8 (10) 10 (11) 11 (11)
Moderate/
poor
70 (90) 69 (90) 82 (89) 92 (89)
TNM 0.471 0.001
1 1 (1) 2 (2) 3 (4) 1 (1)
2 40 (51) 46 (60) 61 (66) 55 (53)
3 28 (36) 19 (25) 14 (15) 40 (39)
4 9 (12) 10 (13) 14 (15) 7 (7)
Wt¼wild type; U¼unmethylated; M¼methylated; TNM¼tumour, node, metastasis.
Location: proximal or distal to splenic flexure.
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sPCR was performed as described in detail elsewhere (Herman et al,
1996; Derks et al, 2004). DNA was first amplified with BNIP3
flanking PCR primers that amplify bisulfite-modified DNA but do
not preferentially amplify methylated or unmethylated DNA. The
resulting template was used as the template for BNIP3 methyl-
ation-specific PCR. For primer sequences see Supplementary Table
1. All PCRs were performed with a control for unmethylated BNIP3
alleles (normal lymphocyte DNA), a positive control for methyl-
ated BNIP3 alleles (Sssl methyltransferase (New England Biolabs,
Beverly, MA, USA)-treated normal lymphocyte DNA) and a
negative control without DNA. Each PCR product was loaded
onto a 2% agarose gel, stained with Gelstar
s (Cambrex Bioscience
Rockland Inc., Rockland, ME, USA) and visualised under UV
illumination.
Immunohistochemistry
Serial formalin-fixed, paraffin-embedded tissues sections (4mm)
were stained for HIF-2a and CA9, as described previously (Cleven
et al, 2007). Brief descriptions are as follows.
HIF-2a staining Antigen retrieval was performed by microwave
treatment (750W for 20min in 1mM TE buffer, pH 8.0), followed
by cooling in buffer for 30min. Slides were blocked in 25% normal
serum for 10min. Sections were incubated with primary antibody
HIF-2a (1:500) for 100min (anti-HIF-2a monoclonal: ab8365;
AbCam, Cambridge, UK).
CA9 staining Slides were blocked in 25% normal serum for
10min, and then incubated for 45min with primary CA9 anti-
body MoAb M75 (1:50, anti-human CA9; kindly supplied by
Dr S Pastorekova) at room temperature.
In addition to the above-mentioned staining procedures, serial
sections were stained for p53, BNIP3 and M30, as follows:
p53 staining Antigen retrieval was performed by microwave
treatment (750W for 15min in Antigen Retrieval (DAKO,
Glostrup, Denmark)), followed by cooling in buffer for 30min.
Slides were blocked in 25% normal serum for 10min. Sections
were incubated for 45min at room temperature with primary
antibody p53 (1:500, anti-p53 monoclonal (DO-7); M7001 DAKO).
BNIP3 staining Antigen retrieval was performed by microwave
treatment (750W for 15min in Antigen Retrieval (DAKO)),
followed by cooling in buffer for 30min. Slides were blocked in
25% normal serum for 10min. Sections were incubated for 180min
at room temperature with primary antibody BNIP3 (1:400, anti-
BNIP3 monoclonal (Ana40); ab10433, Abcam, Cambridge, UK).
M30 staining Antigen retrieval was performed by microwave
treatment (750W for 10min in Antigen Retrieval (DAKO)),
followed by cooling in buffer for 30min. Slides were blocked in
25% normal serum for 10min. Sections were incubated for 45min
at room temperature with primary Cytodeath antibody M30 (1:50,
mouse monoclonal (CloneM30); Roche Applied Science,
Mannheim, Germany).
Each staining protocol was started with pre-incubating in 0.6%
hydrogen peroxide for 20min to block endogenous peroxidase
activity. Furthermore, as a negative control, TBS buffer was used
instead of primary antibody. Visualisation was performed using
Dako Envision, Peroxidase, mouse System (K4001; DAKO).
Powerenvision poly-HRP (50510–60307; Immunologic, Duiven,
The Netherlands) was used for M30 visualisation. The slides were
counterstained with haematoxylin.
Evaluation of immunohistochemistry
Evaluation for HIF-2a and CA9 staining was performed as
described previously in detail (Cleven et al, 2007). Briefly,
localisation (epithelial or stromal) was scored separately. For the
category stromal staining, only the stromal myofibroblasts were
taken into account, not the tumour-infiltrating inflammatory cells
or the lamina propria of the normal mucosa. If nuclear staining
was present in 45% of the tumour epithelial cells or stromal cells,
the sample was considered positive for HIF-2a.
If membranous staining occurred in 45% of the tumour
epithelial cells or stromal cells, samples were considered positive
for CA9 (Yoshimura et al, 2004).
TP53 and BNIP3 staining were considered positive by the
presence of nuclear staining for TP53 and cytoplasmic staining for
BNIP3, in 45% of tumour cells.
M30 expression was documented as the number of positive
M30 cells per square millimetre of tumour cells (counted in 10
high-power fields ( 100) per tumour) (Figures 1C and D).
Apoptosis was categorised as ‘low’ apoptosis when the number of
M30-positive cells p10 (mean) and as ‘high’ apoptosis when
the number of M30-positive cells 410 (Marijnen et al, 2003;
de Bruin et al, 2006).
Data analysis
Correlations between HIF-2a, CA9, BNIP3, TP53, M30 and
clinicopathological parameters were determined by the Pearson
w
2- and Fisher’s exact tests, where appropriate. To evaluate the
relationship between HIF-2a, BNIP3, TP53 and survival, Kaplan–
Meier survival curves were calculated. Differences between groups
were determined by using the Log-rank test. The end point for
analyses was overall survival starting from the day of surgery. All
P-values are two sided and Po0.05 was considered statistically
significant. Correction for multiple comparisons was performed
using the Bonferroni procedure. Patients with unknown and
unspecified scores have been omitted from analyses for that
specific variable. SPSS 12.0 software was used for data analyses.
RESULTS
TP53 mutations
TP53 mutation analysis was successful in 155 out of 195 (79%)
CRCs. Out of the 155 CRCs, 72 (46%) were classified as having
no TP53 mutations, 4 (3%) as having silent mutations and 2 (1%)
as having known common polymorphism (exon 6, codon 213,
CGA4CGG, R/R, refSNP rs1800372) (Table 2). A total of 37% (57
out of 155) CRCs were classified as transactivation-incompetent
missense mutations and 5% (8 out of 155) CRCs as transactivation-
competent missense mutations. Correlations between TP53 and
other variables did not change with respect to the predicted
presence or absence of transcriptional activity of TP53 mutants.
Therefore, in further analyses, CRCs were classified as TP53 wild
type when no mutations, silent mutations or a known common
polymorphism were found, and as mutant TP53 when CRCs had
Table 2 Frequency and type of TP53 alterations
TP53 Mutation No. %
Wild-type 72 (46)
Tr-incom missense 57 (37)
Tr-com missense 8 (5)
Silent 4 (3)
Nonsense 5 (3)
Deletion 4 (3)
Insertion 3 (2)
Polymorphism 2 (1)
Total 155 (100)
Tr-incom¼transactivation incompetent; Tr-com¼transactivation competent.
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classification, 77 out of 155 (50%) CRCs showed TP53 mutations
(Table 1), which is in agreement with data published by others
(Cripps et al, 1994; Pricolo et al, 1997; Borresen-Dale et al, 1998;
Kressner et al, 1999; Tortola et al, 1999; Garrity et al, 2004; Tang
et al, 2004; Conlin et al, 2005; Mollevi et al, 2007; Petitjean et al,
2007).
p53 protein expression was only observed in the nucleus of
epithelial cells (Figure 1A). There was a significant correlation
between the absence of p53 protein expression and wild-type TP53
vs the presence of p53 protein in mutant TP53 (P¼0.029; data not
shown). No correlation was observed between the TP53 mutation
status and clinicopathological data (Table 1).
TP53 mutations, patient survival and apoptosis
Overall, no significant survival difference was observed between
wild-type and mutant TP53 CRCs (data not shown). However,
the previously reported association between HIF-2a- or CA9-
positive CRCs and poor prognosis was found to exist exclusively
in wild-type TP53 CRCs (P¼0.001 and P¼0.0829, respectively;
Figures 2A and B). Furthermore, there was a significant difference
in survival between stromal CA9 expression (38%, 5-year survival)
and epithelial CA9 expression (71%, 5-year survival) within
wild-type TP53 tumours (P¼0.0391, data not shown). Overall
levels of HIF-2a or CA9 expression were not different between
wild-type and mutant TP53 CRCs (data not shown). Survival of
mutant TP53 CRCs was not related to HIF-2a or CA9 expression
(P¼0.9312 and P¼0.8456, respectively; Figures 2E and F). These
data suggest that wild-type TP53 CRCs are less susceptible to the
adverse effects of hypoxia. As TP53 can induce apoptosis during
hypoxia, we assessed the extent of apoptosis (M30 staining; Figures
1C and D). Overall, we found no differences in apoptotic levels
between wild-type and mutant TP53 CRCs (Table 3), or between
HIF-2a- and CA9-positive or -negative CRCs (data not shown).
This was found regardless of the TP53 mutation status. These
results indicate that the presence or absence of functional p53
protein is not decisive for determining the extent of apoptosis in
CRCs.
BNIP3 methylation
BNIP3 promoter methylation analysis was successful in all of the
195 CRCs (100%). Overall, 53% (103 out of 195) CRCs showed
BNIP3 promoter hypermethylation (Table 1), which is in agree-
ment with data published earlier (Murai et al, 2005; Lee and Paik,
2006).
The relationship between protein expression of BNIP3 and
BNIP3 promoter methylation status was analysed in a randomly
selected subset of patients (n¼31). BNIP3 protein expression was
only observed in the cytoplasm of epithelial cells (Figure 1B).
BNIP3 promoter-methylated CRCs less frequently demonstrated
BNIP3 protein expression than unmethylated CRCs (25 vs 75%,
respectively).
BNIP3 methylation, patient survival and apoptosis
Overall, there was no significant survival difference between BNIP3
methylated and unmethylated CRCs (data not shown). Although in
HIF-2a stromal-negative CRCs, BNIP3 methylation occurred in
61% (33 out of 54) and did not influence prognosis, in the HIF-2a-
positive tumours, methylation was observed at almost equal
frequency, 52% (68 out of 132), but was associated with poorer
patient survival (P¼0.006; Figure 2G). Similarly, exclusively
stromal (and not epithelial) expression of CA9 was an indicator
of a poorer prognosis in both BNIP3 methylated and unmethylated
tumours (P¼0.0495 and P¼0.0725, respectively; Figures 2D
and H).
This suggests that hypoxic CRCs with stromal expression of
HIF-2a and CA9 have a poorer prognosis, independent of BNIP3
methylation.
As BNIP3 has been reported to induce apoptosis in response to
hypoxia, its methylation and associated downregulation might be
expected to result in less apoptosis in the HIF-2a subgroup.
However, a low apoptotic activity (low M30 expression) was
Figure 1 (A) Nuclear expression of p53 in colorectal tumour epithelial cells. (B) Cytoplasmic expression of BNIP3 in colorectal tumour epithelial cells.
(C, D) Expression of M30 in colorectal tissue. (C) Expression of M30 in normal colon tissue. (D) Expression of M30 in tumour epithelial cell. (A, B) Original
magnification  20; (C, D) original magnification  40. Black bar pictures: (A, B) 200mm; (C, D) 100mm.
Poor outcome in HIF-2a- and CA9-positive CRCs
AHG Cleven et al
730
British Journal of Cancer (2008) 99(5), 727–733 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sdetected more frequently in BNIP3 unmethylated CRCs 68% (50
out of 73) compared with BNIP3 methylated CRCs 46% (42 out of
91, P¼0.004; Table 3). Although tumours with both methylated
BNIP3 and stromal HIF-2a expression showed a poorer patient
survival when compared with HIF-2a-negative tumours, this was
not related to apoptosis (data not shown). Furthermore, we did not
detect differences in apoptotic levels between tumours with or
without CA9 expression, regardless of the BNIP3 methylation
status.
DISCUSSION
In a previous study on the expression of hypoxia-related markers
(HIF1a, HIF2a, CA9 and GLUT1) in colorectal adenocarcinomas,
we found that in all tumours at least one of these proteins is
immunohistochemically expressed. This indicates that hypoxia is
an all but ubiquitous phenomenon in colorectal tumours. How-
ever, expression of only HIF2a and CA9 in the tumour-associated
stroma was correlated with a poorer prognosis, suggesting that
tumours with this particular phenotype follow a more aggressive
course (Cleven et al, 2007). These results are in contrast to
some other studies on colon and rectum tumours that can be
summarised by the observation that HIF1a and GLUT1 expression
in rectal cancer cells is of prognostic significance (Haber et al,
1998; Yoshimura et al, 2004; Lu et al, 2006; Theodoropoulos et al,
2006). Our finding was relatively new, in the sense that others
have mainly reported the relation between tumour prognosis and
expression of hypoxia markers in cancer cells, without paying
attention to stromal expression. The results in our study did not
differ between tumours of the colon and rectum.
So far, the biological basis of stromal expression of hypoxia-
related markers in CRC is unclear. It could either be a
serendipitous finding, or a genuine indication of altered epithe-
lial–mesenchymal interactions within a subset of tumours. In
these tumours, hypoxia-driven metabolic and cell biological
changes could hypothetically alter the tumour stroma toward an
environment that can facilitate cancer progression, along multiple
routes, leading to an enhanced proliferation or survival of tumour
epithelial cells (Beppu et al, 2008). Under hypoxic conditions, the
tumour stroma can select for the propagation of certain subclones
of cancer cells that are optimally endowed for tumour progression.
A recent study on breast cancer, on how changes in stromal gene
expression affect epithelial tumour progression, showed that gene
expression profiling of microdissected tumour stroma resulted in a
set of stromal genes, which could predict clinical outcome. This set
notably included enhanced stromal expression of hypoxia-
associated genes (Finak et al, 2008).
The current study attempts to pinpoint specific genetic and
epigenetic features of CRC cells, which are both associated with the
observed more aggressive presentation of CRCs expressing HIF2a
and CA9 in their surrounding stroma, and impact on one of the
hallmarks of cancer, namely regulation of apoptosis under hypoxic
conditions.
Table 3 Correlations between BNIP3 methylation and TP53 alteration vs
M30 expression
M30 low M30 high
No. % No. % P
BNIP3
Unmethylated 50 (68) 23 (32) 0.004
Methylated 42 (46) 49 (54)
TP53
Wild-type 39 (56) 31 (44) 0.703
Mutation 36 (59) 25 (41)
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Figure 2 Survival curves. (A) HIF-2a expression in wild-type TP53 group (P¼0.001, n¼75). (B) CA9 expression in wild-type TP53 group (P¼0.0829,
n¼72). (C) HIF-2a expression in BNIP3 unmethylated group (P¼0.1712, n¼83). (D) CA9 expression in BNIP3 unmethylated group (P¼0.0725, n¼79).
(E) HIF-2a expression in mutant TP53 group (P¼0.9312, n¼69). (F) CA9 expression in mutant TP53 group (P¼0.8456, n¼71). (G) HIF-2a expression in
BNIP3 methylated group (P¼0.006, n¼98). (H) CA9 expression in BNIP3 methylated group (P¼0.0495, n¼95). U, unmethylated; M, methylated.
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signals, mediated partly by TP53 and BNIP3 (Brahimi-Horn and
Pouyssegur, 2006). Therefore, it could be envisaged that hypoxia
provides a selective environment for outgrowth of cells in which
these genes have become mutated or silenced. Loss of pro-death
genes, such as TP53 and BNIP3, may result in increased hypoxia
tolerance and cross-resistance to other death-inducing stimuli
associated with metabolic stress or treatment. Immunohisto-
chemical staining showed that TP53 and BNIP3 expressions are
confined to the epithelial cell compartment in CRC, and are not
present in the surrounding mesenchymal cells, making these two
genes interesting candidates to study the hypothesis of cancer cell
selection under hypoxia-driven modification of tumour–stroma
interactions.
Intriguingly, our results indicate that tumours expressing HIF-
2a or CA9 in their stroma have a poorer prognosis in wild-type
TP53 tumours compared with mutant tumours. It is unclear as to
how wild-type TP53 might benefit this tumour subgroup, but
several possibilities exist. Firstly, p53 is involved in a metabolic
switch to glycolysis when oxidative phosphorylation is impaired
during hypoxia (Lum et al, 2007). Also, other means of adaptation
to metabolic stress, such as increased fatty acid b oxidation, have
been shown to be present in tumour cells with intact p53. With
respect to this, increased apoptosis was reported in p53-deficient
HCT-116 CRC cells as compared with wild-type p53 HCT-116 cells,
when challenged by metabolic stress (Buzzai et al, 2007). The
second possibility is that wild-type TP53 does not act directly, but
simply correlates with defects in another pathway, such as the
BNIP3 cell death pathway, which substitutes for TP53 loss in a
similar fashion during carcinogenesis.
With respect to apoptosis- and hypoxia-driven tumour progres-
sion, we did not find important effects related to the mutational
status of TP53. However, apoptotic levels were lower in BNIP3-
expressing tumours, when compared with tumours with epigen-
etically silenced BNIP3 (P¼0.004), which is somewhat surprising
given the fact that functional BNIP3 is thought to induce cell death
downstream of hypoxia inducible transcription factors. Appar-
ently, things are more complicated. BNIP3 may not be restricted to
regulation of apoptosis, but could also regulate other pathways,
such as autophagy, in which there is a delicate balance between cell
survival and cell death (Papandreou et al, 2005). Conceivably, the
lower apoptotic activity in tumours with functional BNIP3 might
be due to autophagic rescue of the tumour cells. Furthermore,
BNIP3 levels appear to modulate cell death not only via apoptosis
or autophagy, but also via necrosis. Also, the net effect of BNIP3 is
determined by the level of expression: too high BNIP3 expression
will lead to autophagic cell death, whereas lower levels of BNIP3
expression, as in cells where BNIP3 is silenced, will induce necrosis
(Tracy et al, 2007). In our study, we used the immunohistochem-
ical marker M30, which exclusively measures apoptotic cell death,
and thus were not able to differentiate between other forms of cell
death, such as autophagic death and necrosis (Leers et al, 1999;
Ueno et al, 2005).
Summarising the results from the current study, levels of
apoptosis do not play an important role in determining the poorer
prognosis of hypoxic CRCs, as defined by stromal expression of
HIF-2a and CA9. However, the latter phenotype is correlated with
the presence of wild-type TP53 in the tumour cells, and the
presence of functional p53 does indeed appear to have an
important impact on poorer prognosis. This prognostic effect is
not established through regulation of programmed tumour cell
death, but may rather be connected to an enhanced capacity for
adequate adaptation to metabolic stress. As TP53 mutations occur
in a relatively early stage of colorectal carcinogenesis, the potential
deleterious effects of hypoxia on CRC biology may already be
programmed in a very early phase of tumour development.
As opposed to TP53, functionally or epigenetically silenced
BNIP3 did not turn out to be of influence in determining tumour
prognosis. Furthermore, preservation of BNIP3 function was
shown to decrease apoptotic activity, and may thus be involved
in enhanced cell survival through autophagic rescue, or could be
implicated in alternative cell death pathways, such as autophagic
cell death or necrosis, which we were unable to measure in our
experimental approach.
The findings in this translational study, on the relation between
expression patterns of hypoxia-related markers in clinical samples
of CRC and the functional status of genetically or epigenetically
modified proteins involved in regulation of tumour cell death
on the one hand and patient outcome on the other, open up
interesting new avenues for more fundamental studies on the
mechanisms underlying tumour hypoxia-induced changes in
epithelial–mesenchymal interactions.
Understanding the mechanisms by which hypoxic tumours can
overcome cell death signals and adapt through metabolic changes
is critical for our understanding of tumour progression and
development of effective therapeutics in CRC patients with adverse
prognostic profiles.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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